GSK exec: Genzyme deal too big to swallow

You've heard GlaxoSmithKline ($GSK) execs say it before, and now they're saying it again: No big mergers. And that includes deals the size of Genzyme, which is scouting about for justification of its refusal to entertain Sanofi-Aventis' ($SNY) $18.5 billion hostile offer. If that scouting raised a white-knight bidder, so much the better. And GSK is one of the companies Genzyme ($GENZ) is said to have contacted.

Not interested, SVP Patrick Vallance maintained during remarks to reporters at a strategy session in Cambridge, Massachusetts. "Those kind of big deals are incredibly destructive to research and development," said Vallance, as quoted by Reuters, adding that the process can lead to chaos. "There is an argument for maintaining a stable R&D organization."

Instead, GSK will continue to focus on smaller deals, partnerships and creative tie-ups. It will leave the Genzyme-type buyouts to other customers, such as Sanofi, which may be averse to megamergers, but figures a $20 billion deal would be workable. Sanofi's $69-a-share bid for Genzyme is set to expire early next month, but the French drugmaker may well extend the tender offer. Whether Genzyme's value-seeking expedition yields anything new by then is anybody's guess.

- read the Reuters piece

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.